Journal profile · Medicine-Cardiology and Cardiovascular Medicine
Cardiovascular and Hematological Disorders - Drug Targets
ISSN 1871-529X · eISSN 2212-4063 · Bentham
Cardiovascular and Hematological Disorders - Drug Targets: subscription journal; median 89 days to acceptance (86 articles, last 24 months); 42 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Cardiovascular and Hematological Disorders - Drug Targets is published by Bentham. By OpenAlex counts of its recent articles, its largest topics are Blood Coagulation and Thrombosis Mechanisms, Atherosclerosis and Cardiovascular Diseases and Lipoproteins and Cardiovascular Health, together about 21.6% of its articles. Its main subfields are Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): Medicine-Cardiology and Cardiovascular Medicine
Main research topics OpenAlex counts of recent articles; shares are approximate
- Blood Coagulation and Thrombosis MechanismsMedicine8.5%
- Atherosclerosis and Cardiovascular DiseasesImmunology and Microbiology7.1%
- Lipoproteins and Cardiovascular HealthMedicine6%
- Platelet Disorders and TreatmentsMedicine5.8%
- Nitric Oxide and Endothelin EffectsMedicine5.3%
- Antiplatelet Therapy and Cardiovascular DiseasesMedicine4.5%
- Acute Myocardial Infarction ResearchMedicine4.2%
- Cholesterol and Lipid MetabolismMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Hematology | Q3 | 99/151 | 34th |
| Cardiology and Cardiovascular Medicine | Q3 | 271/409 | 33rd |
| Pharmacology | Q3 | 246/328 | 25th |
| Molecular Medicine | Q4 | 159/179 | 11th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 1.8LetPub ·
- SJR 2026-06
- 0.24LetPub ·
- SNIP 2026-06
- 0.47LetPub ·
- h-index
- 52OpenAlex ·
- i10-index
- 312OpenAlex ·
- 2-year mean citedness
- 1.21OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 810 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 41 | 1 | 422 |
| 2025 | 42 | 4 | 635 |
| 2024 | 27 | 3 | 667 |
| 2023 | 32 | 2 | 697 |
| 2022 | 33 | 0 | 767 |
| 2021 | 43 | 2 | 717 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
89 daysMedian, submission to acceptance · P25–P75 65 days – 109 days
- Acceptance to online
- median 212 days (86 articles)
- Submission to online
- median 299 days
- Sample
- 86 articles with submission and acceptance dates (98 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham
- ISSN
- 1871-529X
- Electronic ISSN
- 2212-4063
FAQ
Frequently asked questions about Cardiovascular and Hematological Disorders - Drug Targets
How long does peer review take at Cardiovascular and Hematological Disorders - Drug Targets?
Based on the dates recorded on 86 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 89 days (interquartile range 65–109 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cardiovascular and Hematological Disorders - Drug Targets?
According to LetPub and DOAJ records, Cardiovascular and Hematological Disorders - Drug Targets is indexed in Scopus.
Is Cardiovascular and Hematological Disorders - Drug Targets open access, and what is the APC?
Cardiovascular and Hematological Disorders - Drug Targets is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .